Biologic predictors of clozapine response in schizophrenia

Psychiatric Annals

Volumn 26, Issue 7, 1996, Pages 390-394

  Malhotra, Anil K ^a   Pickar, David ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0030500356     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/0048-5713-19960701-07     Document Type: Article

References (35)

1. Malhotra AK, Litman RE, Pickar D. Adverse effects of antipsychotic drugs. Drug Safety. 1993; 9:429-436.
2. Grebb JA, Cancro R. Schizophrenia: clinical features. In Kaplan HI, Sadock BJ, eds. Comprehensive Textbook of Psychiatry. Baltimore, MD: Williams and Wilkins; 1989.
3. Carlsson A, Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol. 1963; 20:140-144.
4. Davis KL, Davidson M, Mohs RC, et al. Plasma homovanillic acid concentrations and the severity of schizophrenic illness. Science. 1985; 227:1601-1602.
5. Pickar D, Labarca R, Doran AR, et al. Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Arch Gen Psychiatry. 1986; 43:669-676.
6. Pickar D, Labarca R, Linnoila M, et al. Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients. Science. 1984; 225:954-957.
7. Bowers MB, Swigar ME, Jatlow PI, Goicoechea N. Plasma catecholamine metabolites and early response to haloperidol. J Clin Psychiatry. 1984; 45:248-251.
8. Crow TJ. Molecular pathology of schizophrenia: more than one disease process? BMJ. 1980; 280:66-68.
9. Kane J, Honigfeld G, Singer J, Meltzer H, the Clozaril Collaborative Study Group. Clozapine for the treatment resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988; 45:789-796.
10. Pickar D, Owen RR, Litman RE, Konicki E, Gutierrez R, Rapaport MH. Clinical and biologic response to clozapine in patients with schizophrenia: crossover comparison with fluphenazine. Arch Gen Psychiatry. 1992; 49:345-353.
11. Farde L, Nordstrom A, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry. 1992; 49:538-544.
12. Pickar D. Prospects for pharmacotherapy of schizophrenia. Lancet. 1995; 345:557-562.
13. Szymanski S, Lieberman J, Pollack S, et al. Clozapine effects on neuroendocrine response to apomorphine challenge testing in chronic neuroleptic nonresponsive schizophrenia: preliminary findings. Biol Psychiatry. 1995; 37:52-55.
14. Gejman PV, Gelernter J. Mutational analysis of candidate genes in psychiatric disorders. Am J Med Genet. 1993; 48:184-191.
15. Van Tol HHM, Bunzow JR, Guan HC, et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature. 1991; 350:610-614.
16. Seeman P, Guan HC, Van Tol HHM. Dopamine D4 receptors elevated in schizophrenia. Nature. 1993; 365:441-445.
17. Van Tol HHM, Wu CM, Guan HC, et al. Multiple dopamine D4 receptor variants in the human population. Nature. 1992; 358:149-152.
18. Rao PA, Pickar D, Gejman PC, Ram A, Gershon ES, Gelernter J. Allelic variation in the D4 dopamine receptor (DRD4) gene does not predict response to clozapine. Arch Gen Psychiatry. 1994; 51:912-917.
19. Breier A, Buchanan RW, Waltrip RW, Listwak S, Holmes C, Goldstein DS. The effect of clozapine on plasma norepinephrine: relationship to clinical efficacy. Neuropsychopharmacology. 1994; 10:1-7.
20. Davidson M, Kahn RS, Stern RG, et al. Treatment with clozapine and its effect on plasma homovanillic acid and norepinephrine concentrations in schizophrenia. Psychiatry Research. 1993; 46:151-163.
21. Green AI, Alam MY, Sobieraj JT, et al. Clozapine response and plasma catecholamines and their metabolites. Psychiatry Research. 1993; 46:139-149.
22. 2 antagonist, augments fluphenazine in schizophrenic patients: a pilot study. J Clin Psychopharmacol. 1993; 13:264-267.
23. Meltzer HY. The mechanism of action of novel antipsychotic drugs. Schizophr Bull. 1991; 17:263-287
24. Owen RR, Gutierrez-Esteinou R, Hsiao J, et al. Effects of clozapine and fluphenazine treatment on responses to m-chlorophenylpiperazine infusions in schizophrenia. Arch Gen Psychiatry. 1993; 50:636-644.
25. Kahn RS, Davidson M, Knott P, Stern RG, Apter S, Davis KL. Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Arch Gen Psychiatry. 1993; 50:599-605.
26. Risch SC, Lewine RRJ. Low cerebrospinal fluid homovanillic acid-5- hydroxyindoleacetic acid ratio predicts clozapine efficacy: a replication. Arch Gen Psychiatry. 1993; 50:670.
27. Kahn RS, Davidson M, Siever L, Gabriel S, Apter S, Davis KL. Serotonin function and treatment response to clozapine in schizophrenic patients. Am J Psychiatry. 1993; 150:1337-1342.
28. Risch SC, Lewine RRJ. Clozapine therapy and increases in homovanillic acid. Arch Gen Psychiatry. 1995; 52:244.
29. Szymanski S, Lieberman J, Pollack S, et al. The dopamine-serotonin relationship in clozapine response. Psychopharmacology. 1993; 112:885-389.
30. 2A receptor gene. Lancet. 1995; 345:281-282.
31. 2A receptor gene and the antipsychotic response to clozapine. Am J Psychiatry. In press.
32. White FJ, Wang RY. Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science. 1983; 221:1054-1057.
33. Deutch AY, Lee MC, Iadarola MJ. Regionally specific effects of atypical antipsychotic drugs on striatal FOS expression: the nucleus accumbens shell as a locus of antipsychotic action. Mol Cell Neurosci. 1992; 3:332-341.
34. Cohen RM, Nordahl TE, Semple WE, Andreason P, Litman RE, Pickar D. The brain metabolic patterns of clozapine- and fluphenazine-treated schizophrenic patients: compensation, not normalization. Arch Gen Psychiatry. In press.
35. Buchsbaum MS, Potkin SG, Marshall JF, et al. Effects of clozapine and thiothixene on glucose metabolic rate in schizophrenia. Neuropsychopharmacology. 1992; 6:155-163.